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Abstract
Leprosy is a worldwide health problem, which needs the development of new and inno-
vative strategies to be controlled. Early diagnosis of leprosy is an important contribution 
to reducing the incidence of the disease; thus, the development of biotechnology plat-
forms, which include the mapping of antigens with potential to be used in immunodiag-
nostic and molecular methods for the detection of Mycobacterium leprae, is an important 
tool to confirm the clinical diagnostic. Molecular biology and biotechnological methods 
have been used to assist in the diagnosis of this disease, each one with its advantages 
and drawbacks. Enzyme-linked immunosorbent assay (ELISA) is the used method for 
leprosy diagnosis, and it allows the detection of infection-related antigens. Alternatively, 
due to their versatility to perform the same functions as the protein and non-protein 
natural antigens, mimetic peptides are considered an important tool. On the other hand, 
lateral flow assay (LFA) and optical and electrochemical biosensors are rapid and por-
table methods, capable of performing diagnosis in the field without sample preparation. 
This chapter presents such techniques, their uses in the diagnosis and detection of M. 
leprae, as well as the potential for the development of new techniques and strategies that 
can help to control and understand mycobacteriosis.
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1. Introduction
Leprosy is a chronic infectious disease, dermato neurological and incapacitating, which has 
Mycobacterium leprae as its causal agent [1]. Even with the worldwide effort to eliminate this 
disease as a public health problem [2], countries such as India and Brazil still present a higher 
number of cases than the World Health Organization (WHO) recommended [3]. In this sense, 
this organization defined as a global strategy the reduction in the incidence of new cases as a 
priority [4], highlighting the importance of early diagnosis, which aims to reduce the trans-
mission of the disease in the community [5], which includes correctly diagnosing cases with 
suspicion of the disease and to identify subclinical infection.
The clinical and epidemiological diagnosis of leprosy represents the gold standard for confir-
mation of the disease [6]. Bacilloscopy and Mitsuda’s reaction are important tests to identify 
the etiological agent [7, 8], but there is a need to use complementary tests that allow a more 
accurate diagnosis with high sensitivity and specificity. In this context, stand out the stan-
dardization of serological and molecular tests, important for the understanding of the epide-
miological profile of the disease.
The use of M. leprae specific antigens in serological tests has been the subject of research. The 
use of phenol-glycolipid-1 (PGL-1) [9], lipoarabinomannan (LAM) [1] and heat shock proteins 
(GroES and GroEL) [10] as antigens for the enzyme-linked immunosorbent assay (ELISA) and 
in immunosensors can be validated as methods for detecting new cases of the disease and for 
early diagnosis [11]. In addition, molecular tests aid in the identification of specific M. leprae 
sequences in clinical samples, which can be amplified through the polymerase chain reaction 
(PCR) technique, allowing DNA detection of the infectious agent [12] and/or through the 
use of real-time PCR technology that allows the evaluation of bacterial load [13] and also the 
monitoring of drug resistance [14].
Thus, this chapter will present an overview of the laboratory diagnosis of leprosy in the 
world. Initially, we will present a review of the main tests traditionally used in clinical rou-
tine and regulated by the WHO, in addition to the complementary tests that have been focus 
of research as a future perspective for the early diagnosis of the disease. These diagnostic 
approaches may contribute to a reduction in the number of cases of the disease, since they 
allow the monitoring of populations and endemic and hyperendemic areas.
2. Leprosy diagnosis: traditional exams
The diagnosis of leprosy includes clinical observation of the patient, dermato-neurological 
clinical exams and complementary laboratory tests. Therefore, identify lesions and damaged 
nerves and analyze the life history of the patient are essential tools in the identification and 
detection of disease. These practices combined with other tools and methodologies are able 
to assist in epidemiological and disease control strategies, helping to map index cases and 
individuals who may develop leprosy, such as household contacts.
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2.1. Dermato-neurological clinical exam, bacilloscopy, histopathology and 
Mitsuda test
For the diagnosis of leprosy, it is essential to perform clinical-dermatological exams that 
search for lesions in the epidermis, areas with changes in sensitivity (may be thermal, painful 
and tactile) and motor impairment-searching for thickened nerve trunks-which are classic 
signs of the disease [7]. In addition to clinical examination, there is a class of diagnostic exams 
and tests that are widely standardized and used in reference networks and centers [7, 15].
Bacilloscopy is the most commonly used exam in clinical practice and, together with the 
dermato-neurological clinical test, is the most useful methodology for diagnosis [16]. The 
test presents advantages such as reduced cost and aid in the confirmation of new cases and 
patients with relapse [15]. The methodology used to perform the exam is a dermal smear of 
sites, these being: ear lobes (LO), elbows (C) and active lesions, where it is possible to analyze 
the presence of the bacillus using a specific staining and optic microscopy [17, 18].
As a result, a Bacilloscopy Index (BI), proposed by Ridley and Joplin, is provided, where 
there is a logarithmic scale ranging from 0 to 6 [19–21]. Thus, after an average of the fields 
analyzed, the result may vary from BI = 0, associated with patients of the tuberculoid (TT) 
pole and BI = 3+ to 6+, associated with lepromatous patients (LL). It is still possible to analyze 
the morphological index (MI) of the bacilli arranged on the slide, describing aspects of their 
morphological integrity [20]. Thus, bacilli may present three aspects related to their struc-
ture, classified as integral, fragmented or granular [21, 22]. Integral bacilli are considered 
viable, that is, they are related to host susceptibility to the parasite. These bacilli exhibit cell 
structure with preserved ends and uniform staining and are seen in smears of patients who 
are either non-treated or have relapse. Both fragmented and granular bacilli present flaws 
in the cell wall structure, being considered unviable or dead and more observed in post-
treatment patients [17–22].
Bacilloscopy is effective when associated with the results of clinical exams [7, 15]. However, 
it is an exam that presents low sensitivity, since 50% of the smears of the sick individuals are 
negative. In addition, the exam requires adequate laboratory infrastructure and trained pro-
fessional apparatus, factors that are not always a reality in hyperendemic regions and where 
medical and financial resources are reduced [7].
Histopathology is commonly performed for the diagnosis of diseases caused by obligate 
intracellular parasites and has good indices of sensitivity and specificity in the detection of 
leprosy [23]. However, the method encounters issues related to cost, time of analysis and 
false-negative results, besides of being an invasive exam [24]. Exactly for these reasons, his-
topathology is only recommended for individuals where it is impossible to assess degrees of 
cutaneous sensitivity, such as in children, elderly and mentally handicapped people; when it 
is not possible to classify the dimorphic clinical form; or when there is uncertainty whether 
the diagnosis is leprosy or other diseases that cause local hypoesthesia [23]. The diagnosis 
using this exam also depends on the association with the clinical aspects and bacilloscopy. 
In addition, biopsies of peripheral nerve branches are not recommended and should only be 
performed in the last instance [23, 24].
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The Mitsuda test or Mitsuda reaction does not present diagnostic value, but it is an alterna-
tive prognostic tool that assists in assessing susceptibility to lepromatous forms [27]. It is an 
exam based on the use of heat-killed bacilli (lepromin), derived from extract of the inactivated 
“leprosy bacillus” under the skin of LL patients. The test consists of inoculating the Mitsuda 
antigen intradermally and reading them between days 21 and 28 after the challenge in order 
to analyze the late cellular response of patients [8, 25].
Mitsuda’s reaction has good agreement when related to bacilloscopy. Typically, individuals 
with a diameter reaction greater than 10 mm are considered resistant; they do not get sick or 
develop the TT shape, being Mitsuda positive [24]. While reactions with a diameter between 3 
and 5 mm are indicative of dimorphic leprosy and, below this value, the test indicates anergy of 
the host’s immune system to the bacillus, associated with patients in the LL pole, being Mitsuda 
negatives [8, 24, 26]
3. Complementary immunological tests
The discovery of the lipid apparatus present in the bacillus capsule and the characterization 
of a range of important lipidic and proteic components in the immunogenicity [30] allowed 
innovations in the leprosy serology [27].
Serological techniques are based on the detection of specific antibodies against the bacillus, 
since immunoglobulin production occurs in response to the antigenic signal of stimulation. 
These tests are important because they represent a class of complementary tests capable of 
detecting leprosy cases, besides the possibility of diagnosis recommendation, disease preva-
lence determination, infection evaluation in endemic and hyperendemic areas, and house-
hold contacts monitoring.
3.1. ELISA with native PGL-1 and its synthetic molecules
Many researches have used natural M. leprae antigens for the immunodiagnosis of leprosy 
[19, 28]. The elucidation of the structure of the PLG-1-the first M. leprae specific antigen to be 
isolated and the main antigenic glycolipid of the bacillus [29]-is a clear example of the wide-
spread use of these molecules.
ELISA (enzyme-linked immunosorbent assay) has been widely used as a research tool for the 
detection of anti-PGL-1-native antibodies [29–32]. The technique consists of a quantitative test 
based on the IgM class antibodies response. In this scenario, important aspects in the biology 
and epidemiology of the disease, such as the determination and comparison of the positivity of 
patients and home contacts in several areas, besides the fluctuations in the reactivity profile in 
individuals from the hyperendemic area [33, 34] have been described from the studies with PGL-1.
Anti-PGL-1 antibodies are present in large numbers in untreated multibacillary patients, but 
paucibacillary patients naturally have low circulating antibody concentrations. For this reason, 
some of these patients present negative results against the diagnosis, even showing positive 
clinical signs [35, 36].
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In addition, there’s still a great limitation in obtaining the native molecule, restricted to the 
growth of M. leprae in armadillos. As an alternative, several synthetic analogous molecules 
associated with the tri or disaccharides of PGL-1 have been produced from the conjugation of 
these elements with BSA (Bovine serum albumin) and Phenol (P) or Octyl (O). The literature 
shows several semisynthetic analogues, among which the most well known are: monosaccha-
ride-octyl-BSA (MO-BSA), disaccharide-BSA (D-BSA), natural disaccharide-octyl-BSA, natu-
ral octyl-HSA (ND-O -BSA and ND-O-HSA), natural trisaccharide-phenol-BSA (NT-P-BSA) 
which are used as antigens in immunodiagnosis [30, 36].
A study carried out in the hyperendemic region of the Brazilian Amazon points to the poten-
tial of synthetic molecules to identify new cases of leprosy and, similar to glycolipid, they have 
good detection rates in multibacillary patients. In addition, research shows that the molecules 
exhibit behavior related to the spectral immunology of the disease, where the LL pole has a 
higher antibody titer that decays at the boderline and tuberculoid poles [35]. When compar-
ing two molecules derived from PGL-1 in the region, it was possible to observe that NT-P-BSA 
was very effective in the monitoring of home contacts and MB patients, whereas ND-O-BSA 
obtained better sensitivity and specificity indices in paucibacillary individuals [37].
ELISA requires skilled labor and specific equipment which is not always available. Therefore, 
the use of serological tests of both the native molecule and synthetic derivatives is important 
to validate increasingly adequate methods for the seroepidemiology of both endemic and 
hyperendemic regions, besides helping to standardize the positivity indices of the clinical 
forms that can vary intensely from one area to another.
3.2. ELISA with recombinant proteins
If the characterization of PGL-1 was important for the synthesis of several derived molecules 
with similar immunological aspects, the decoding of the M. leprae genome was essential for 
the identification of proteins and peptides with applicability in the laboratory detection of the 
disease [38]. Several advantages are associated with the use of these molecules, especially for 
reducing the cost of the assays and reflecting the spectral character of leprosy immunology. 
Thus, assays using recombinant proteins indicate high levels of antibodies in LL patients that 
decay in patients of the boderline and tuberculoid poles [38–43].Currently, there are a large 
number of M. leprae recombinant proteins, normally identified as ML, and several studies 
have evaluated the potential of these proteins [44]. In 2007, a survey conducted in Brazil, 
the Philippines and Japan evaluated the cellular and humoral response to 33 recombinant 
proteins across a broad population spectrum and identified three proteins (ML0405, ML2055 
and ML2331) capable of inducing the humoral response in multibacillary (MB), production 
of IgG, as well as the cellular response in PB. Comparison between sites identified differen-
tial response patterns between populations, however, in all locations ML0405 and ML2331 
showed similar results to PGL-1 serology in MB33 patients [40].
Due to the potential of these two proteins, the Leprosy IDRI Diagnostic protein (LID-1) was 
generated, resulting from the fusion between the two MLs. LID-1 was produced in order to 
maintain the reactivity profile of both proteins and was subsequently evaluated in several 
populations of Japan, Brazil, Venezuela, the Philippines and Nepal. The results pointed to the 
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potential of early detection of the disease using this protein, besides the possibility of its immo-
bilization in different platforms [40].
Also in this scenario, in 2009 a chimeric protein with multiple epitopes (PADL), from the 
fusion of epitopes of recombinant proteins (ML0405, ML0049, ML0050, ML0091, ML0411, 
ML2055 and ML2311) was designed. The chimeric molecule was tested in serum from pauci 
and multibacillary patients living in Brazil and the endemic controls from the Philippines. 
The results demonstrated that all the portions that formed the protein have specific bind-
ing capacity to antibodies and the same showed great effectiveness in the diagnosis of MB 
patients and no specific response to the serum of the endemic controls, showing promise in 
the diagnosis of the disease [45].
3.3. Lateral flow tests
In addition to the ELISA immunoassays, leprosy serology may also be performed with the 
lateral flow test, known as ML-flow. The development of this immunochromatographic semi-
quantitative assay was due, in particular, to the possibility of field use. The test was developed 
by Burker-Sékula et al. [46], aiming the detection of IgM antibodies against several antigenic 
molecules such as PGL-1 and its synthetic derivatives, recombinant proteins and peptides [30].
The ML-flow test is not a diagnostic method, but assists in the classification of patients and pres-
ents low cost and easy execution, making its use possible in health services routine, especially 
in regions where laboratory resources are not available [30, 35, 46, 47]. Therefore, ML-flow is 
a methodology widely used in hyperendemic areas, especially in Brazil, where populations of 
Maranhão, São Paulo, Pará and Minas Gerais states were tested and reaffirm the importance of 
detection and control of disease cases through simple but reliable methodologies [32, 48–52].
In the search for increasingly fast and accurate tests, in 2012 the Brazilian Institute of Infectious 
Research together with the company OrangeLife developed a test capable of offering a diag-
nosis in only 10 minutes using only one drop of blood of the patient. The tool has received 
approval from the Brazilian National Sanitary Surveillance Agency (ANVISA) and has been 
field tested to evaluate the potential of the new platform. The assay is based on immunochro-
matography aspects, where recombinant proteins like LID-1, used as antigen, are immobi-
lized on nitrocellulose membranes. Detection can be performed by the presence of IgM and 
IgG antibodies from various samples such as whole blood, plasma and serum.
Among the advantages of the test, it is mentioned the low cost of the tool, the possibility of 
early detection, agile and minimally invasive. In addition, it is associated with software stored 
on smartphones, further facilitating the interpretation of the exam and ensuring the availabil-
ity of information in databases. Parallel analyzes of the rapid detection tool show the ability 
to diagnose, in most cases, the presence of the infection before clinical symptoms appear, 
contributing to the generation of accurate diagnoses and quality.
The interdisciplinary researches related to leprosy provided an amount of laboratory tools used as 
alternative methodologies for the more accurate and efficient diagnosis of the disease. Although 
there are still difficulties linked to the detection of paucibacillary forms, subclinical infections and 
contact monitoring, all research reinforces the importance of the search and use of efficient plat-
forms and able to ally reduced cost and good indexes of sensitivity and specificity for the disease.
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4. Complementary molecular tests
After the advent of the genome sequencing of the M. leprae bacterium [53], species-specific 
genetic sequences have been searched in order to standardize diagnostic tests based on DNA 
analysis. These sequences can be amplified through the PCR technique, which allows the 
detection of bacillus DNA from small amounts of M. leprae cells [12].
The first works using the PCR technique were performed a little over 20 years, but the data 
were not satisfactory for the identification of M. leprae DNA in paucibacillary (PB) patients 
[54]. Thus, the methodology of molecular biology began to be used as an alternative method 
to traditional diagnostic methods. These data stimulated the search for new specific sequences 
for the identification of the bacillus, as well as the use of several clinical samples [55].
Many studies have been carried out involving different sequences and target genes, with 
the aim of increasing sensitivity and specificity in the identification of bacillus, especially in 
patients with low bacillary load. The literature reports the use of sequences that amplify gene 
regions encoding the 36 kDa [56], 18-kDa [57] and 65-kDa antigens [58], complex 85 [59], 16S 
rDNA [60] as well as for repetitive sequences of M. leprae (RLEP) [61]. By comparing these 
sequences, RLEP has been shown to be more sensitive and more specific than the bacilloscopic 
index. This could be explained by the number of copies, estimated to be at least 28 units, 
of the RLEP sequence in the M. leprae genome. In addition, this sequence generates a 130pb 
amplicon, which is considerably small compared to the sequences mentioned above, that is 
an important factor in the best efficiency in conventional PCR. Having a specific sequence is 
of great importance, since the PCR technique may be useful in the differential dermatological 
diagnosis [62].
A significant advance in increasing bacillus identification occurred with the use of real-time 
PCR technology. This methodology has been used in the follow-up of leprosy patients under-
going treatment [63] evaluation of bacterial load [13] viable bacterial load [60] and determina-
tion of resistance to treatment [14].
In clinical practice, detection of M. leprae by PCR in patients with negative bacilloscopy or 
inconclusive histopathology is of great value to define the correct diagnosis and treatment 
scheme [64]. In the same way, the methodology can be useful, for those patients with the pure 
neural form (PNL), who usually do not have cutaneous lesions and because of this they have 
deficient treatment scheme [65, 66]. Further, the PCR technique may be useful in early iden-
tification, since a considerable number of studies have addressed the positivity of M. leprae 
DNA in contacts of leprosy patients [48, 67–69].
In a study carried out in a hyperendemic area in cases of leprosy, it was possible to identify 
DNA from the bacterium in buccal and nasal swab samples in individuals with subclinical 
infection with multibacillary or paucibacillary index cases [48]. The identification of DNA 
from the Hansen bacillus in buccal and nasal swab raises considerations about the participa-
tion of this risk group in the transmission chain, besides the route of infection of the bacillus 
[70]. Although PCR can be a useful tool for identification, few studies associate the presence 
of M. leprae DNA to the development of the disease [71, 72], highlighting the importance of 
the use of serological tools and the follow-up of patients with subclinical infection [73, 69]
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5. New biotechnological tools in the diagnosis of leprosy
5.1. Mapping of new markers
Many studies have used post genomic procedures for the discovery of new antigens that can 
be used in the diagnosis of leprosy [71–75]. These studies have explored sequences of M. leprae 
for the identification of proteins or peptides that can be used in the serodiagnosis of the differ-
ent clinical forms of leprosy [76].
The antigens ML0405, ML2331 and ML2055—the first two of previously unknown function 
and the latter a membrane protein - were used for serological tests in in multibacillary patients 
of the clinical forms boderline lepromatous (BL) and LL untreated [77]. The ML0308 and 
ML2498 proteins, a conserved hypothetical protein and an enoyl-CoA hydratase respectively, 
showed humoral and cellular immunogenicity and can be used in the diagnosis of tuberculoid 
and lepromatous forms [78]. These antigens were used in the production of fusion proteins, 
such as LID-1 (leprosy IDRI diagnostic-1) [42] and PADL [45, 79].
The tools of bioinformatics, genomic analysis and proteomics are also being used for map-
ping in silico of important antigenic targets of M. leprae [80]. This type of analysis was used to 
define a group of 50 potential antigens in mycobacteria, some being restricted to M. leprae [78].
Peptides derived from specific and immunogenic proteins of M. leprae have also been tested 
in patients with leprosy and controls [81]. Peptides obtained of proteins from M. leprae were 
promising as indicators of exposure [82].
The peptides are small in size and can be expressed on the surface of bacteriophage to select 
peptides that mimic different targets (pathogens, cellular receptors or antibodies) [83]. Mimetic 
peptides may have important applications in the diagnosis of leprosy, mimicking antigens 
such as PGL-1 [84] or other M. leprae antigens [85, 86]. Alternatively, due to their versatility to 
perform the same functions as the protein and non-protein natural antigens, mimetic peptides 
are considered an important tool in immunodiagnostic of infectious disease.
5.2. Biosensors as platforms for the diagnosis of leprosy.
The post-genomic, the identification and obtainment of hundreds of molecules with immu-
nogenic potential have broadened the versatility of detection platforms and contributed to 
an optimal diagnostic test, especially for tropical diseases [87]. In recent decades, biosensors 
have been gaining more space in scientific research and diagnosis of various diseases [88].
Biosensors are analytical devices that have specific reactions and/or specific interactions medi-
ated by a diversity of components (antigens, antibodies, enzymes, DNA fragments, organelles, 
receptors and even mimetic peptides) that, in contact with a transducer, have the conversion 
of a biological signal-a result of the interaction between specific components-in a measurable 
signal proportional to the analyte concentration [89]. These platforms can be electrochemical, 
piezoelectric, thermal, optical and based on surface plasmon resonance, depending on the 
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type of transducer used [90]. There are still specific classes of biosensors such as immunosen-
sors [91], which evaluate interactions between antibodies and antigens, and genosensores, 
based on the hybridization of DNA-specific ribbons [87].
There is a wide range of studies showing the efficacy of biosensors for the detection of various 
diseases such as leishmaniasis, bacterial diseases, cystic fibrosis, dengue and leprosy itself [92–
96]. In Brazil, a genosensor for M. leprae was constructed using the immobilization of a bacillus 
single-stranded DNA (ssDNA) on functionalized graphite electrodes. The interaction between 
the immobilized sequence and M. leprae double-stranded DNA (dsDNA) is measured electro-
chemically by reductions in the peak oxidation current and using ferrocenecarboxyaldehyde as 
the hybridization indicator. The result was very promising, showing efficient detection in only 3 
minutes [87, 88, 96].
Currently, Brazilian research groups are betting on the use of electrochemical biosensors 
as an indispensable tool in the diagnosis and control of diseases. This innovation is mainly 
because these sensors are sensitive, reliable, fast response and operate in conditions that pre-
treat the samples. In addition, these techniques are capable of providing exceptionally low 
detection limits.
In this scenario, mimetic peptides of proteins and glycolipids present in the bacillus capsule 
have been validated for the immunogenic potential and immobilized in these electrochemical 
detection platforms. Thus, the proposals consist of using different biological fluids such as 
blood, secretion and saliva, ensuring a less invasive and more comfortable test to the patient 
and the manipulator. Subsequently, these platforms will be tested in hyperendemic areas, in 
order to evaluate their detection potential and help in the epidemiological control of the disease.
6. Conclusion
The early diagnosis of leprosy is one of the goals of the WHO for the control and reduction 
of new cases of the disease. This strategy will be implemented with the development of new 
diagnostic tools more sensitive and can be applied in large-scale monitoring. Molecular tech-
niques and new biotechnological approaches can be used as complementary tests.The qualita-
tive PCR, RLEP and real time PCR have been used for the detection of M. leprae in samples of 
different tissues of patients or of household contacts.
Immunodiagnosis can be done using different native M. leprae antigens such as PGL-1, LAM or 
their synthetic derivatives. Post-genomic technologies can be used for the production of recom-
binant chimeric proteins, peptides obtained in silico or mimetic peptides. Immunodiagnosis 
can be performed by ELISA, lateral flow tests and biological sensors.
Biotechnology and molecular biology have contributed to the development of research and 
improve the diagnosis of leprosy. Significant advances in laboratory diagnosis contribute to 
improving clinical practice.
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